References
- Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356–361
- Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(Suppl 2:ii)11–16
- Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 238–242
- Cho TJ, Edgar C, Sadeghi C, Hou A, Einhorn TA, Gerstenfeld LC. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. Arthritis Rheum 2003; 48(10)2845–2854
- Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991; 10: 4025–4031
- Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, Schett G. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006; 54: 463–472
- Kim HA, Song YW. Apoptotic chondrocyte death in rheumatoid arthritis. Arthritis Rheum 1999; 42: 1528–1537
- Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 2003; 3: 317–322
- Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006; 11: 1709–1726